Ovarian Studies

A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer (NEKTAR:08-PIR-04):

• Histologically or cytologically confirmed diagnosis of epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer
• Inoperable metastatic or locally advanced disease

Quick Links: Regional Cancer Center Virtual Tours Behavioral Health Services Home Care Network Pain Management Palliative Care Wound Center SparrowRobotics.org

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-Sensitive Ovarian Cancer in First Relapse. (MORAb-003-004-A):

• Female subjects >/= 18 years of age
• Histologically or cytologically confirmed diagnosis of non-mucinous epithelial ovarian cancer